<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/29DA934B-D3A6-439B-9995-881F280D33E4"><gtr:id>29DA934B-D3A6-439B-9995-881F280D33E4</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Thornhill</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FN001265%2F1"><gtr:id>4E9115EA-D76A-4EE4-9BBA-FE6721C05147</gtr:id><gtr:title>HIV-1 Reservoir in Gut-Associated Lymphoid Tissue (GALT) in Primary HIV Infection</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/N001265/1</gtr:grantReference><gtr:abstractText>HIV is a chronic disease that can be well controlled with daily medications, known as antiretroviral therapy (ART). Usually ART is not started straight away, but only after immune cells (CD4 T-cells) have fallen below a set level. Although ART has dramatically improved survival for people living with HIV, it cannot cure HIV and so once started, treatment is life-long. This is because current ART cannot remove HIV from cells containing virus in a resting state - known as the HIV reservoir. For this reason virus levels return and people can become unwell if ART is stopped. Lifelong ART is challenging due to drug side effects, treatment fatigue, viral drug-resistance and expense. Whilst curing HIV infection is not possible with ART alone, a period of time off treatment without detectable virus in the blood - &amp;quot;remission&amp;quot; maybe feasible and is highly attractive.

Recent studies have shown that if ART is started immediately after an individual becomes infected with HIV a lower level of viral reservoir can be achieved than for those starting treatment in later stage disease. Unexpectedly, amongst some rare individuals treated from early infection, virus did not return to high levels even after therapy is stopped; this is called post-treatment control (PTC).

Using current laboratory tests to measure HIV reservoir in blood cannot accurately predict who might achieve PCT. One reason blood tests measuring viral reservoir may not accurately predict PTC may be that the rebounding virus is not coming from blood cells. There are different HIV reservoirs in the body from which the virus can return; the largest is the gut which can be five times larger than the reservoir in the blood. It is hypothesized that virus that returns after ART is stopped maybe coming from reservoirs within the Gut-associated lymphoid tissue (GALT).
 
To address this question, my key aim is to characterise and compare measures of viral reservoir in gut samples with those from blood from people who have started on early ART. This will be a sub-study of an ongoing study of treated early infection called HEATHER which is evaluating blood biomarkers of viral reservoir. Participants enrolled into the HEATHER study will be invited to additionally agree to an endoscopy where small samples of gut will be taken for research evaluation of viral reservoirs. These biopsy tests are routine procedures and will be performed by a doctor who specialises in such procedures at St Mary's Hospital in London. We will analyse the blood and gut samples using specialised laboratory tests at the University of Oxford in order to assess the types of cells which make up the reservoir and the amount of HIV in the gut reservoir compared with blood. We then aim to investigate if gut reservoir measures can predict which patients might safely interrupt ART and achieve PTC. Ultimately this will be tested by giving the option of interrupting treatment (as part of a study) but only amongst a very small number of patients deemed most likely to achieve PTC based on our study results. The results of this work will inform other studies which test new treatments aimed at curing HIV by helping the investigators to decide who can stop treatment without the virus returning.</gtr:abstractText><gtr:technicalSummary>Aims:
This project aims to determine if measurement of HIV-1 reservoir in Gut-Associated Lymphoid Tissue (GALT) can predict post-treatment control (PTC).
Relevance:
Recent cases of PTC of HIV - where virus does not rebound after cessation of ART commenced during primary HIV infection (PHI) - suggest a remission or functional cure is possible. Accurate predictors of PTC are needed to allow safe stopping of ART. Current viral reservoir quantification assays from blood have not predicted PTC, suggesting an alternative source of rebounding viraemia. I propose that the terminal ileum is a key productive reservoir and that quantification of HIV reservoir at this site will predict PTC.
Objectives:
1.To establish a GALT HIV-reservoir sub-study from the HEATHER cohort involving ileal and rectal biopsies.
2.To develop and apply virological and immunological assays to characterise the HIV reservoir in GALT and compare with equivalent measures in blood using established assays/platforms.
3.To develop a predictive algorithm of PTC, that will include GALT and blood biomarkers. This will be tested amongst selected individuals with a Treatment Interruption(TI) in the HEATHER study.

Methodology:
&amp;gt;130 individuals are enrolled and have donated blood samples to the HEATHER study. I will enrol to a GALT sub-study (n=55). Using Ileal and rectal biopsies, I will apply assays of HIV reservoir and immunophenotyping to CD4+ cells from GALT; including Total and integrated DNA, HIV-1 intracellular viral unspliced RNA transcripts, Next Generation Sequencing of Provirus and immunophenotyping using FACS. The measures of reservoir in GALT will be compared with blood and together will inform an algorithm to PTC. 
Scientific and medical opportunities:
The project will provide a a detailed analyses of sustained ART on the GALT reservoir and the role of GALT biomarkers in predicting PTC. Such biomarker data will allow for development of safe TI protocols in HIV cure intervention trials.</gtr:technicalSummary><gtr:potentialImpactText>The benefits resulting from a HIV cure are many spanning across medical, scientific, social and economic spheres. While this research would not lead to HIV cure itself it aims to address the question of how to predict those who may have been successful in achieving &amp;quot;remission&amp;quot; and could safely contemplate a period of time off therapy, or cured by novel therapeutic interventions, thereby contributing to a body of evidence with the ultimate goal of HIV cure. 
 
The key intended beneficiaries from this research are people living with HIV. Currently there is no cure or vaccine for HIV-1 infection. Approximately 35 million people are infected with HIV-1 - 0.8% of the global adult population; in the UK an estimated 100,000 individuals are living with HIV. Antiretroviral therapy (ART) has dramatically improved survival for those living with HIV, and has been an extremely successful intervention; however it requires provision of life-long ART to all who need it, which is a challenge, and also is associated with toxicity, drug resistance and treatment fatigue. Feedback from community groups of people living with HIV suggests that a drug free remission of HIV as opposed to a sterilising cure would be a greatly valued option. While this research would not directly offer a cure for HIV, it aims to provide data which can pave the way for future interventions studies by identifying biomarkers which may allow for safe stopping of ART. 
 
ART is an expensive intervention as it requires high cost medications and treatment is life-long. HIV care including ART costs the National Health Service approximately &amp;pound;1 billion per year. Consequently steps towards a cure or remission for HIV would have a clear economic benefit. This is even more relevant in regions of the world where the human and economic burden of HIV disease is greatest, such as sub-Saharan Africa. 
 
The short-term beneficiaries of this research are those involved in designing cure intervention studies with new therpeutic agents. The data generated aims to allow identification of individuals who will not have viral rebound on stopping of ART. This will be done by interrogating the role of the HIV proviral reservoir in the gut, and in particular in the terminal ileum as opposed to rectum, in comparison to PBMC, which may act as a more sensitive indicator of the HIV reservoir. It will also be of particular interest to those researching sanctuary sites of HIV reservoir, and those examining the mechanisms of HIV persistence in the gut. Ultimately this will benefit those involved in translational and clinical HIV research.</gtr:potentialImpactText><gtr:fund><gtr:end>2018-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2015-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>266784</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>The CHERUB Collaboration (Collaborative HIV Eradication of viral Reservoirs: UK BRC)</gtr:description><gtr:id>286877F4-F342-43E4-A69C-B26C5E66404B</gtr:id><gtr:impact>doi: 10.1038/ncomms9495
doi: 10.1097/QCO.0000000000000123
doi: 10.1097/QAI.0000000000001013</gtr:impact><gtr:outcomeId>58c296469d58c9.99656701-1</gtr:outcomeId><gtr:partnerContribution>My MRC research training fellowship project has involved working across two Universities, namley Imperial College and University of Oxford. This has been facilitated by the CHERUB collaboration, and has allowed me the opportunity to benefit from the research and technical training required to carry out my project. In additon it's has allowed me access to equipment and flow cytometry facilities that would not have been otherwise avaliable.</gtr:partnerContribution><gtr:piContribution>CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC) is a collaboratio of Internationally-recognised researchers from five Biomedical Research Centers, who are working together to provide a unique experimental medicine approach to new HIV therapeutic strategies. The aims of Cherub are to develop and promote a coordinated UK-wide response to explore strategies targeting HIV eradication and remission. In addition it has developed biobank of samples for use in scientific research by the collaborative parties.

Through my MRC funded work, I contribute data and expertise on HIV persistence in tissue reservoirs, more specifically gut-associated lymphoid tissue.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>The Peter Medawar day</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>93AADBB6-10E6-491C-B20B-33BB08467FD4</gtr:id><gtr:impact>The Peter Medawar day is a research symposium where each research group working at the Peter Medawar Building for Pathogen Research at the University of Oxford showcase their recent work. I had an opportunity to present my work at this event in 2016</gtr:impact><gtr:outcomeId>58c29a6a778f08.24845477</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>HEATHER Study patient feedback event</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>C59CD558-F34D-4970-9498-20BBD2636D0E</gtr:id><gtr:impact>This patient feedback event was held at Imperial College and attended by approximately 25 study participants. It involved an update for participants on the conference abstracts and publications resulting from the HEATHER study. This was an relatively informal and interactive platform, we recieved positive feedback from the study participants and sparked a dialogue with patient groups as to community priorities for this research in the future.</gtr:impact><gtr:outcomeId>58c2992ba59241.12683793</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Study participants or study members</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>10000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BHIVA Research Awards 2015</gtr:description><gtr:end>2017-01-02</gtr:end><gtr:fundingOrg>British HIV Association (BHIVA)</gtr:fundingOrg><gtr:id>7BC71280-8E0A-4812-ACA5-82E114481110</gtr:id><gtr:outcomeId>57348dbcb86b47.99046428</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>IAS 2015 Towards an HIV Cure Symposium Scholarship</gtr:description><gtr:end>2015-08-02</gtr:end><gtr:fundingOrg>International AIDS Society (IAS)</gtr:fundingOrg><gtr:id>20D761F3-9EE5-4492-B33E-3127A3FAA1CA</gtr:id><gtr:outcomeId>57349013481e98.75585432</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2015-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Citation in British HIV Association Guidelines</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:guidelineTitle>BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015</gtr:guidelineTitle><gtr:id>289F2827-9888-49FA-9F8F-11F7DC542BB3</gtr:id><gtr:outcomeId>58c29bfcab3707.26923557</gtr:outcomeId><gtr:type>Citation in clinical guidelines</gtr:type><gtr:url>http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>4E812CE7-A393-4A02-994F-4B570AD4193A</gtr:id><gtr:title>A pilot evaluation of whole blood finger-prick sampling for point-of-care HIV viral load measurement: the UNICORN study.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5aa65ac0700ea6.87589085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>17454033-EAA7-45E6-9ADE-2FFAEE7FC04B</gtr:id><gtr:title>Advancing the HIV cure agenda: the next 5 years.</gtr:title><gtr:parentPublicationTitle>Current opinion in infectious diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0951-7375</gtr:issn><gtr:outcomeId>57348ada09b644.47343418</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7C01D683-8D68-44CA-AACE-A2B9A3B59A71</gtr:id><gtr:title>Impact of timing of ART on HIV DNA; findings from HEATHER, an observational cohort study</gtr:title><gtr:parentPublicationTitle>HIV MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2e76bf5341e035f21daf2f684b615b2"><gtr:id>b2e76bf5341e035f21daf2f684b615b2</gtr:id><gtr:otherNames>Thornhill J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c29f3dc2de17.14787130</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47B8A422-5F47-40A1-A72A-1AE8F76BD42A</gtr:id><gtr:title>The Role of CD4+ T Follicular Helper Cells in HIV Infection: From the Germinal Center to the Periphery.</gtr:title><gtr:parentPublicationTitle>Frontiers in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/0422310b7b85faad60b4329c6ae24ec2"><gtr:id>0422310b7b85faad60b4329c6ae24ec2</gtr:id><gtr:otherNames>Thornhill JP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1664-3224</gtr:issn><gtr:outcomeId>5899e21d8f1e50.52324214</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5C93F52D-D6B1-4EA4-A47F-5DC3CE6E7EF2</gtr:id><gtr:title>Immunological biomarkers predict HIV-1 viral rebound after treatment interruption.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d8ec98240adbc03a6bc8db72fed0b1d8"><gtr:id>d8ec98240adbc03a6bc8db72fed0b1d8</gtr:id><gtr:otherNames>Hurst J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>57348be1536630.65150037</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B0AFC69-9A41-4B3D-A0DB-EE3F3764B9C0</gtr:id><gtr:title>IAS Towards an HIV Cure Symposium: people focused, science driven: 18-19 July 2015, Vancouver, Canada.</gtr:title><gtr:parentPublicationTitle>Journal of virus eradication</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2055-6640</gtr:issn><gtr:outcomeId>5899e3612a3c22.04813774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5B88416E-A14A-42F0-9264-815DA752ECE6</gtr:id><gtr:title>Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>57348ad98e3533.54928727</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8B148990-D033-48D0-AEAC-16DF5F7F9381</gtr:id><gtr:title>Uptake of immediate antiretroviral therapy in primary HIV infection: To treat or not to treat?</gtr:title><gtr:parentPublicationTitle>HIV MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b2e76bf5341e035f21daf2f684b615b2"><gtr:id>b2e76bf5341e035f21daf2f684b615b2</gtr:id><gtr:otherNames>Thornhill J.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c29f3d71bbc0.82176414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>320B41FD-9B09-4AFF-8BEA-FBD7405431DF</gtr:id><gtr:title>Post-treatment control: a functional cure for HIV</gtr:title><gtr:parentPublicationTitle>Future Virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5396838a64e07f0e26ca612ba419eddb"><gtr:id>5396838a64e07f0e26ca612ba419eddb</gtr:id><gtr:otherNames>Thornhill J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:outcomeId>57348c964172f8.97205521</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0662288C-27B6-424C-B84E-A112B3AA825F</gtr:id><gtr:title>Approaches to recruitment of patients presenting with Primary HIV Infection (PHI) into clinical studies</gtr:title><gtr:parentPublicationTitle>HIV MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7123228831b455f143539dc980416a09"><gtr:id>7123228831b455f143539dc980416a09</gtr:id><gtr:otherNames>Mahay K.</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1464-2662</gtr:issn><gtr:outcomeId>58c29f3d9fe671.45228633</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F2D33CCE-BE8F-4F6C-B3F0-E517A4BF2ECF</gtr:id><gtr:title>Virological Blips and Predictors of Post Treatment Viral Control After Stopping ART Started in Primary HIV Infection.</gtr:title><gtr:parentPublicationTitle>Journal of acquired immune deficiency syndromes (1999)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2d9df44b6c9d4866d2f12eaaf87afc68"><gtr:id>2d9df44b6c9d4866d2f12eaaf87afc68</gtr:id><gtr:otherNames>Fidler S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1525-4135</gtr:issn><gtr:outcomeId>5899e14e5a8aa7.09280223</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>98DF0AB8-E56D-4A72-AEFB-3D966E3AD442</gtr:id><gtr:title>Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection.</gtr:title><gtr:parentPublicationTitle>AIDS (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef922613a50f9dbe25b1e6f369d66d77"><gtr:id>ef922613a50f9dbe25b1e6f369d66d77</gtr:id><gtr:otherNames>Martin GE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0269-9370</gtr:issn><gtr:outcomeId>5a5cce9d0e8773.22632515</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/N001265/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>